Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
Quick Read Ocugen (OCGN) completed enrollment of 140 patients in its Phase 3 retinitis pigmentosa trial for OCU400, with topline data expected in Q1 2027 and a rolling BLA submission targeted for Q3 2026. The company's pipeline addresses rare blinding diseases with no approved treatments, including geographic atrophy where existing therapies generate over $1B annually but require frequent injections, while Ocugen's one-time gene therapy approach could capture significant market share if approved. Oppenheimer initiated coverage with an Outperform rating and $10 price target, betting that Ocugen's gene-agnostic approach to retinitis pigmentosa will succeed where the only existing approved therapy, Luxturna, is limited to a single gene mutation. The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE Oppenheimer initiated coverage of Ocugen NASDAQ:OCGN ) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stag
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story [Yahoo! Finance]Yahoo! Finance
- Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts [Seeking Alpha]Seeking Alpha
- Ocugen (OCGN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.MarketBeat
- Ocugen: Downgrading After OCU410 Data Release [Seeking Alpha]Seeking Alpha
- Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 3/5/26 - Form 3
- 3/4/26 - Form S-8
- 3/4/26 - Form 10-K
- OCGN's page on the SEC website